Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
March 2013, Vol 4, No 3
March 2013, Vol 4, No 3
Onyx Pharmaceuticals 360™: A Support Program for Patients with Multiple Myeloma and Their Caregivers
By
Joanne Buzaglo, PhD
;
Vicki Kennedy, LCSW
;
Jennifer Sharretts, MBA
March 2013, Vol 4, No 3
Background:
In 2007, the Institute of Medicine’s
Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs
outlined a framework to integrate psychosocial health services into routine care for patients with cancer.
Read Article
Ochsner CEO Calls for Adding Value in Healthcare
By
Caroline Helwick
Health Policy
,
Policies & Guidelines
March 2013, Vol 4, No 3
New Orleans, LA—“We must start to think differently if we want to change the healthcare system,” said Ochsner Health System President and CEO Warner L. Thomas, CPA, MBA, FACHE, in a keynote address at the 2013 Health Information and Management Systems Society (HIMSS) annual conference.
Read Article
Knowledge Gaps and Value-Based Oncology Coverage Related Findings from the 2012 National Employer Survey
By
Cheryl Larson, BA
;
F. Randy Vogenberg, PhD, RPh, FASHP
March 2013, Vol 4, No 3
Background:
Healthcare costs are a continued concern among employers and other purchasers, and extend especially to biologics that are being increasingly scrutinized to demonstrate value over time. A significant cost challenge to employers, these drugs create logistical issues for patients, physicians, pharmacies, and manufacturers owing to their unique approval requirements, dosing, side effects, and distribution methods. The costs of biologics are also hard to track, because they show up in medical as well as pharmacy expenditures.
Read Article
Evaluating Payer Restrictions on Prostate Cancer Treatments
By
Melinda C. Haren
;
Kati Sadiwnyk
;
Joseph Tucciarone
March 2013, Vol 4, No 3
Background:
According to the National Institutes of Health, medical expenditures are projected to reach $158 billion by the year 2020. This represents a 27% increase from 2010 costs. Prostate cancer is in the top 5 contributors of this cost, and is projected to reach $12 billion. Advancements in drugs, surgery, and radiation therapy have all contributed to an increase in costs. Payers are feeling increased pressure to make cost-effective choices among these agents.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma